Transforming clinical research and science in bronchiectasis: EMBARC3, a European Respiratory Society Clinical Research Collaboration

Bronchiectasis is a major health problem that is increasing in prevalence and burden globally [1, 2]. The impact of bronchiectasis on patients and the healthcare system is exacerbated by the decades in which the disease was under-recognised, under-researched and poorly treated [3]. There remain no treatments licensed by regulatory authorities worldwide, and many of the treatments that are used in routine clinical practice lack robust evidence [4]. Therapeutic development in bronchiectasis is undermined by the lack of experimental models and a lack of fundamental understanding of the disease. This makes bronchiectasis less attractive for investment into new therapeutic research compared to other fields. EMBARC3 is a programme of clinical and translational research aiming to improve our understanding of bronchiectasis globally <https://bit.ly/42n3HD8> We thank Celine Genton and Elise Heuvelin from the European Respiratory Society (Lausanne, Switzerland) for logistical support.